Solvonis Therapeutics (LSE:SVNS) has published a new analysis of existing Phase 2 KARE trial data for its ketamine-based candidate SVN-001 in severe alcohol use disorder. The analysis reports a statistically significant 67% reduction in heavy drinking days against placebo in one late time window, while the wider pooled result did not reach significance.

What was announced

On 29 September 2026 Solvonis Therapeutics plc (LSE:SVNS) released new analyses of data from KARE, a randomised Phase 2 trial of adjunctive ketamine in alcohol use disorder (AUD) led by Professor Celia Morgan at the University of Exeter. Solvonis uses the trial data for SVN-001 under a collaboration arrangement. The results are a reanalysis of a completed study rather than a readout from a new trial.

The company said both analyses have been submitted for peer review and that the heavy-drinking-day findings are available as a preprint on medRxiv. SVN-001 and SVN-002 remain investigational and unapproved.

The numbers

The headline figures reported by the company are:

  • 67% fewer heavy drinking days than placebo at weeks 17 to 20 (p=0.018, statistically significant)
  • 55% reduction pooled across weeks 17 to 24 (p=0.062, not significant at conventional thresholds)
  • significant increases in days abstinent across all measured windows
  • significant reductions in craving and rumination at three months, with a larger response on both measures among patients with a family history of AUD

The company set these against published results for other treatments: relative reductions of 25% for naltrexone (Vivitrol), 35% for the GLP-1 candidate pemvidutide and 46% for semaglutide. These are indirect cross-trial comparisons, not head-to-head data, and differences in trial populations, designs and time points limit what they can show. The KARE participant number is not stated in the announcement.

Solvonis also highlighted dosing. SVN-001 is given as a short, defined four-week course, compared with monthly injections for Vivitrol and ongoing weekly regimens for GLP-1 therapies. The company presents this as a point of difference; no cost or adherence data are given.

What the company says

Chief Executive Anthony Tennyson said: "SVN-001 now has both a mechanism and data." He said the treatment eases the craving and negative thinking that drive relapse and that, on the endpoint the European Medicines Agency uses, it is ahead of the standard of care and the GLP-1 therapies. That is the company's characterisation, based on the cross-trial comparison.

Chief Scientific Officer Professor David Nutt said: "It's one thing to show a treatment works. It's another to understand why, and to know how it compares. These analyses give us all three."

The company cites company-derived estimates of 12.5 million people with severe AUD in the UK and EU4 (France, Germany, Italy and Spain) and 11.3 million people with moderate-to-severe AUD in the US. It states that these are epidemiological figures, not estimates of treated, treatment-seeking or eligible patients. It also cites an estimated annual cost of AUD to England of about £27.4 billion, of which £4.9 billion falls on the NHS.

What to watch next

The UK Phase 3 MORE-KARE trial, with 280 participants and co-funded by the NIHR, is recruiting and is designed to test the family-history hypothesis directly. The company has said it plans to expand the programme into Europe. No timing for Phase 3 results is given in the announcement.

Separately, SVN-002, an oral thin-film formulation of esketamine, is advancing towards a US Phase 2 programme after a completed pre-IND meeting with the US Food and Drug Administration.

The next points of reference are the outcome of peer review for the two analyses and progress in MORE-KARE recruitment. The announcement contains no financial information or funding update.